P16 but not retinoblastoma expression is related to clinical outcome in no-special-type triple-negative breast carcinomas

Modern Pathology

Volumn 27, Issue 2, 2014, Pages 204-213

  Bogina, Giuseppe S ^a   Lunardi, Gianluigi ^a   Marcolini, Lisa ^b   Brunelli, Matteo ^b   Bortesi, Laura ^a   Marconi, Marcella ^a   Coati, Francesca ^a   Valerio, Matteo ^a   Guerriero, Massimo ^b   Massocco, Alberto ^a   Pegoraro, Maria C ^c   Zamboni, Giuseppe ^a  

^a SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c ULSS 5 Ovest Vicentino   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CK5 PROTEIN; PROTEIN; PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG RESPONSE; FOLLOW UP; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; AGED, 80 AND OVER; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROGNOSIS; RETINOBLASTOMA PROTEIN; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84893748029     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.137     Document Type: Article

References (0)